Professor Samuel Ato Duncan, President General of COA Research & Manufacturing Limited Company (COA-RMLC), addressed the press today, Tuesday, 14th May, 2024 at the Exim Bank Hall, Accra, to clarify key issues surrounding the company’s products.
Professor Duncan began by highlighting COA-RMLC’s journey, from its inception in 2006 to the development of its groundbreaking formula and the introduction of COA FX, later reclassified as a herbal medicine for general well-being and renamed COA Mixture.
He also announced the expansion of the product line with COA Plus Mixture and COA MT Mixture in 2023.
“The COA formula is unique and confidential, and only one individual has complete knowledge of the production process.” He stated.
He, however, addressed concerns about brand misuse, warning customers to beware of individuals claiming to sell products with similar benefits to COA Mixture at lower prices.
“Beware of individuals claiming to sell products with similar benefits to COA Mixture at lower prices.” Professor Samuel Ato Duncan said.
Regarding price variations, Professor Duncan explained that COA-RMLC works collaboratively with distributors to ensure fair and reasonable pricing.
“While COA Mixture has maintained a consistent retail price of GHS100 since 2016, some distributors may adjust prices slightly to cover operational costs.” Professor Samuel Ato Duncan said.
The President General also clarified the distinctions between COA products, explaining that COA Mixture promotes general well-being, COA Plus Mixture targets immune system support, and COA MT Mixture specifically addresses malaria.
He further disclosed that unauthorized marketing materials falsely promoting COA products as cures for various diseases, emphasizing that these products are not registered cures and should not replace traditional medical treatment for serious illnesses.
“COA Mixture promotes general well-being, COA Plus Mixture targets immune system support, and COA MT Mixture specifically addresses malaria. These products are not registered cures and should not replace traditional medical treatment for serious illnesses.
“We pledge to provide consumers with precise details and guarantee responsible use of COA products.” He added
COA-RMLC remains committed to advancing natural medicine and invites stakeholders to join its groundbreaking journey in developing plant-based cellular therapies.